Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

C.R. Bard

This article was originally published in The Gray Sheet

Executive Summary

Firm's Avitene Ultrafoam is the first collagen hemostat sponge approved for all surgical applications, including neurosurgery, which comprises just under 50% of the hemostat market, according to the company. The product does not require the addition of thrombin prior to use, significantly cutting the preparation time, the company notes. The sponge complements Bard's existing Avitene line, marketed by its Duval sales force
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel